PTAB Refuses Post-Grant Reviews Of 2 Psilocybin Patents

By Adam Lidgett (June 23, 2022, 5:47 PM EDT) -- The Patent Trial and Appeal Board has said it won't be reviewing a pair of patents on large-scale production of psilocybin for medicinal purposes, saying the patent challenger wasn't likely to succeed in its cases.

In two decisions from Wednesday, a panel of administrative patent judges denied bids from Freedom to Operate Inc. for post-grant reviews of U.S. Patent Nos. 10,947,257 and 10,954,259, which are held by Compass Pathways.

In both cases, the panel said Freedom to Operate "has not demonstrated that it is more likely than not that any of the claims challenged in the petition[s] are unpatentable."

For one...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!